WORK Medical Technology Group LTD
WOK evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for WOK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · WOK
WORK Medical Technology Group LTD is a China-based medical device company that develops, manufactures, and sells medical consumables and equipment through a large distributor network, with a market-oriented R&D approach and recent capital raising activities.
Key risk: Dependence on distributor relationships
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Sep 30, 2025.
Tracking 11 clinical trials · 2 catalysts for WORK Medical Technology Group LTD.
WORK Medical Technology Group LTD is a China-based medical device company that develops, manufactures, and sells medical consumables and equipment through a large distributor network, with a market-oriented R&D approach and recent capital raising activities.
- As of September 30, 2025, the company reported cash & equivalents of $4.1M, shareholders' equity of $9.9M, and total debt of $6.4M [sec].
- The company's PRC subsidiaries sold products through approximately 1,026 domestic distributors and 57 exporting distributors as of fiscal year ended September 30, 2025, covering 34 provincial regions in China and over 30 countries [sec · filed 2026-01-30].
- R&D investment was $435,311 for fiscal year ended September 30, 2025, representing 4.42% of total revenue [sec · filed 2026-01-30].
- The company has filed a Form F-3 registration statement (File No. 333-289943) and entered into securities purchase agreements for Class A and Class B ordinary shares [sec · filed 2026-08-14].
What works
- Extensive distribution network: 1,026 domestic distributors covering all 34 provincial-level regions of China and 57 exporting distributors across six continents, reaching over 30 countries [sec · filed 2026-01-30].
- Market-oriented R&D approach that cooperates with universities, hospitals, and medical institutions to align product development with real market demand [sec · filed 2026-01-30].
- Growing R&D investment: R&D spending increased from $301,644 (2.22% of revenue) in fiscal 2023 to $435,311 (4.42% of revenue) in fiscal 2025 [sec · filed 2026-01-30].
What to weigh
- Negative operating cash flow: net cash used in operating activities was $2,228,087 for the fiscal year ended September 30, 2024 [sec · filed 2025-02-14].
- Dependence on distributor relationships: the company's product development, marketing, and sales rely on maintaining strong working relationships with customers, distributors, and sales agents [sec · filed 2026-01-30].
- Highly competitive and rapidly changing environment with new risks emerging that are difficult to predict [sec · filed 2026-08-14].
- Limited cash position: only $4.1M in cash & equivalents as of September 30, 2025, against $6.4M in total debt [sec].
From the filings
Quoted directly from source documents.
The company had 1,026 domestic distributors and 57 exporting distributors as of fiscal year ended September 30, 2025.
“ended September 30, 2025, 2024, and 2023, they had approximately 1,026, 953, and 892 domestic distributors and 57, 29, and 22 exporting distributors, respectively.”
SEC filings · January 30, 2026
R&D spending was $435,311 for fiscal year ended September 30, 2025, representing 4.42% of total revenue.
“For the fiscal years ended September 30, 2025, 2024, and 2023, the PRC subsidiaries invested $435,311, $302,511, and $301,644 in purchasing tooling, equipment, raw materials, and paying researchers' salaries, accounting for 4.42%, 2.63%, and 2.22% of our total revenue, respectively.”
SEC filings · January 30, 2026
The company operates in a very competitive and rapidly changing environment.
“Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for us to predict all risk factors”
SEC filings · August 14, 2026
Catalyst timeline
- 2026-10-01 · Phase 2 Start: A Prospective, Multicenter, Open-label Two Cohort Study Evaluating the Safety and Efficacy of Select — Initiation of a Phase 2 clinical study to evaluate safety and efficacy of a product candidate.
- 2026-11-01 · Phase 2 Start: A Randomized, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy — Initiation of a randomized Phase 2 study to assess safety, pharmacokinetics, pharmacodynamics, and efficacy of another product candidate.
Risks & what to watch (4)›
Key risks
- Dependence on distributor relationships — Product development, marketing, and sales depend on maintaining strong relationships with customers, distributors, and sales agents [sec · filed 2026-01-30].
- Negative operating cash flow — Net cash used in operating activities was $2,228,087 for fiscal year ended September 30, 2024 [sec · filed 2025-02-14].
- Limited cash position relative to debt — Cash & equivalents of $4.1M as of September 30, 2025, compared to total debt of $6.4M [sec].
- Competitive and rapidly changing environment — New risks emerge frequently and are difficult to predict, potentially impacting business and financial condition [sec · filed 2026-08-14].
What to watch
- Monitor the company's ability to maintain and grow its distributor network, which is critical for revenue generation [sec · filed 2026-01-30].
- Track R&D spending trends and any new product approvals or clearances from regulatory authorities [sec · filed 2026-01-30].
- Watch for updates on the Form F-3 registration statement and any securities purchase agreements that may affect capital structure [sec · filed 2026-08-14].
- Observe operating cash flow trends to assess the company's path to positive cash generation [sec · filed 2025-02-14].
Sources: SEC filings · Generated August 25, 2026 · How we verify sources →
Run WORK Medical Technology Group LTD through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available WORK Medical Technology Group LTD facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
D/E 0.65
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~32d
10 buys · 5 sells (180d)
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$240
| Holder | Shares | Value |
|---|---|---|
| north star investment management corp. | 200 | $240 |
Short Interest
as of May 22, 2026- % of float
- 5.4%
- Days to cover
- 2.6
- Shares short
- 66,020
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
WOK short interestFrequently asked questions
What is the AI investment thesis for WORK Medical Technology Group LTD?
WORK Medical Technology Group LTD is a China-based medical device company that develops, manufactures, and sells medical consumables and equipment through a large distributor network, with a market-oriented R&D approach and recent capital raising activities.
What is WORK Medical Technology Group LTD's next catalyst?
WORK Medical Technology Group LTD's next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Prospective, Multicenter, Open-label Two Cohort Study Evaluating the Safety and Efficacy of Select" — expected October 1, 2026.
Who is the CEO of WORK Medical Technology Group LTD?
Mr. Shuang Wu is the chief executive officer of WORK Medical Technology Group LTD (WOK).
Where is WORK Medical Technology Group LTD headquartered?
WORK Medical Technology Group LTD (WOK) is headquartered in Hangzhou, China.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.